How to purify photoreceptors from retina grown in a dish

9 Sep 2015, 4:54 p.m.

Image shows Rhodopsin CD73

Work recently published in Stem Cells has shown that photoreceptor cells can be grown and purified in the lab before being transplanted into a mature host retina. This research, led by BRC-supported Professor Jane Sowden, suggests that cell replacement therapy involving the transplantation of new photoreceptor cells, isolated from retina grown in a dish, may be a possible treatment for blindness.Retinal diseases causing loss of the light-sensing photoreceptor cells in the retina are a major cause of blindness worldwide. These conditions are largely untreatable. Current research is aiming to develop photoreceptor cell therapy as a future treatment for blindness due to photoreceptor cell death.

Stem cell cultures offer an inexhaustible source of new photoreceptor cells for cell therapy. Stem cells grown under certain conditions have the ability to form three dimensional eye cups containing layers of retinal cells resembling the embryonic eye.

In this study, the team showed for the first time that photoreceptor cells suitable for transplantation can be isolated from stem cell-derived retina using specific tags, termed biomarkers, which are located on the surface of the cells.

The next step following these proof-of-concept studies is to develop similar strategies for the purification of human photoreceptor cells from stem cell cultures for clinical photoreceptor cell therapy.

Ancient gene mutation found as the cause of rare hereditary condition for GOSH patient.

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).

Scientists build whole functioning thymus from human cells

Researchers from two leading national organisations have rebuilt a human thymus using human stem cells and a bioengineered scaffold thanks to support from the NIHR GOSH Biomedical Research Centre (BRC). Their work, which has been published in Nature Commu

Leukaemia trial shows promise and complexity of genome-edited cell therapies

A ‘one size fits all’ immune therapy developed at the UCL Great Ormond Street Institute of Child Health (ICH) could help to clear cancerous cells in children and adults who have exhausted all other treatment options for B-cell acute lymphoblastic leukaemi

GOSH researchers join experts in warning of the detrimental impact of a no deal Brexit on rare diseases

Experts have warned that a ‘no deal’ Brexit will result in the exclusion of the UK from the 24 European Reference Networks (ERNs) that were established to improve the care of patients bearing the lifelong burden of a rare disease, which require highly spe